Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | USP2 | O75604 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
| ▸ | ACHE | P22303 | 5/20 | 0.54 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.54 |
| ▸ | GRIN2A | Q12879 | 3/20 | 0.54 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.54 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.54 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.54 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.54 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.54 |
| ▸ | BAZ2B | Q9UIF8 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.53 |
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4137872 | 0.90 | L3MBTL1 (0.67) | L3MBTL1USP2ACHEGRIN1GRIN2A | |
| SCHEMBL3716723 | 0.85 | L3MBTL1 (0.61) | L3MBTL1USP2ACHEGRIN1GRIN2A | |
| SCHEMBL3720548 | 0.85 | L3MBTL1 (0.61) | L3MBTL1USP2ACHEGRIN1GRIN2A | |
| SCHEMBL3725452 | 0.85 | L3MBTL1 (0.61) | L3MBTL1USP2ACHEGRIN1GRIN2A | |
| SCHEMBL3717707 | 0.85 | L3MBTL1 (0.61) | L3MBTL1USP2ACHEGRIN1GRIN2A | |
| SCHEMBL3724639 | 0.85 | L3MBTL1 (0.61) | L3MBTL1USP2CYP1A2CYP2C9ACHE | |
| SCHEMBL3716546 | 0.85 | L3MBTL1 (0.61) | L3MBTL1USP2ACHEGRIN1GRIN2A | |
| SCHEMBL3726688 | 0.85 | ACHE (0.65) | L3MBTL1USP2ACHEGRIN1GRIN2A | |
| SCHEMBL3721038 | 0.84 | L3MBTL1 (0.60) | L3MBTL1USP2ACHEGRIN1GRIN2A | |
| SCHEMBL4128216 | 0.82 | L3MBTL1 (0.57) | L3MBTL1USP2ACHEGRIN1GRIN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9181240-B2 | Tetracyclic compounds | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-11-10 | — | — | US | disclosed |
| US-9096591-B2 | Tetracyclic compounds | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-08-04 | — | — | US | disclosed |
| US-20150182509-A1 | TETRACYCLIC COMPOUNDS | MEDIVATION TECHNOLOGIES, INC. | 2015-07-02 | — | — | US | disclosed |
| US-9034880-B2 | Tetracyclic compounds | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-05-19 | — | — | US | disclosed |
| US-8999978-B2 | Tetracyclic compounds | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-04-07 | — | — | US | disclosed |
| US-20140194414-A1 | TETRACYCLIC COMPOUNDS | MEDIVATION TECHNOLOGIES, INC. (US) | 2014-07-10 | — | — | US | disclosed |
| US-20130203746-A1 | TETRACYCLIC COMPOUNDS | MEDIVATION TECHNOLOGIES INC. | 2013-08-08 | — | — | US | disclosed |
| US-20130190304-A1 | TETRACYCLIC COMPOUNDS | MEDIVATION TECHNOLOGIES, INC. (US) | 2013-07-25 | — | — | US | disclosed |
| US-20130131054-A1 | TETRACYCLIC COMPOUNDS | MEDIVATION TECHNOLOGIES, INC. (US) | 2013-05-23 | — | — | US | disclosed |
| US-8338408-B2 | Tetracyclic compounds | MEDIVATION TECHNOLOGIES, INC. (US) | 2012-12-25 | — | — | US | disclosed |
| US-20090239854-A1 | Tetracyclic compounds | MEDIVATION TECHNOLOGIES, INC. | 2009-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150182509-A1 | TETRACYCLIC COMPOUNDS | HTR2C, HTR3D, HTR5A | L3MBTL1 3804/4885USP2 2172/4885CYP1A2 2499/4885 |
| US-20130131054-A1 | TETRACYCLIC COMPOUNDS | HTR2C, HTR3D, HTR5A | L3MBTL1 3804/4885USP2 2172/4885CYP1A2 2499/4885 |
| US-20130203746-A1 | TETRACYCLIC COMPOUNDS | HTR2C, HTR3D, HTR5A | L3MBTL1 3804/4885USP2 2172/4885CYP1A2 2499/4885 |
| US-20130190304-A1 | TETRACYCLIC COMPOUNDS | HTR2C, HTR3D, HTR5A | L3MBTL1 3804/4885USP2 2172/4885CYP1A2 2499/4885 |
| US-20090239854-A1 | Tetracyclic compounds | HTR2C, HTR3D, HTR5A | L3MBTL1 3804/4885USP2 2172/4885CYP1A2 2499/4885 |
| US-20140194414-A1 | TETRACYCLIC COMPOUNDS | HTR2C, HTR3D, HTR5A | L3MBTL1 3804/4885USP2 2172/4885CYP1A2 2499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.